While the dollar amount is small, the cluster involves the CEO and three other C-suite officers selling within a week, unusual for a pre-commercial biotech with a single pipeline asset. This may signal insider caution ahead of a binary catalyst (sebetralstat data or regulatory update). Monitor for any 8-K or press release in the next 2-4 weeks.
How the stock moved after the report
⚠ Clustered BEARISH VIEWSTOCK BELOW ENTRY AT T+5- T+0 · May 20 $26.81entry
- T+1 · 6mo ago −0.15%α −0.34% · $26.77
- T+5 · 6mo ago −0.07%α −1.31% · $26.79
- T+20 · due 5mo ago Pending
- T+60 · due 3mo ago Pending
Price Chart
REPLAYWatch the reaction play outHow similar events traded
Executive Summary
Three C-suite insiders at KalVista (CEO, CMO, CDO) sold a combined $87K in open-market sales on May 18, 2026, at $26.76/share. This follows a separate cluster of CMO and CFO sales on May 21-22 totaling $112K, including derivative exercises. Total insider selling of ~$199K over 7 days is modest relative to the $1.4B market cap (0.014%), but the cluster involves the CEO and multiple senior executives, which is notable for a pre-commercial biotech awaiting a pivotal catalyst.
Key Financial Metrics
Key Facts
- CEO Benjamin Palleiko sold 1,100 shares for $30K on May 18
- CMO Paul Audhya sold 1,000 shares for $28K on May 18, plus 2,685 shares for $72K on May 22
- CDO Christopher Yea sold 1,100 shares for $30K on May 18
- CFO Brian Piekos sold 1,489 shares for $40K on May 22
- Total open-market sales in cluster: $87K (0.006% of market cap)
- Combined with prior 5-day cluster: ~$199K total insider sales (0.014% of market cap)
- CMO and CFO also exercised stock options (non-cash) on May 21
- KalVista is a pre-revenue biotech with a $1.4B market cap, awaiting sebetralstat (hereditary angioedema) catalyst
Financial Impact
Total insider sales of ~$199K, or 0.014% of $1.4B market cap, economically trivial in absolute terms
Risk Factors
- Insider sales may be 10b5-1 plan-driven or for tax/estate planning, not informational
- Dollar amount is tiny relative to market cap, could be routine portfolio rebalancing
- Pre-commercial biotech stock prices are driven by pipeline catalysts, not insider trading patterns
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 1 SEC document filed with EDGAR.
| Document | Accession Number |
|---|---|
| CLUSTER Data (Synthetic) | cluster-KALV-1779838419890 |
Track record
12 reports on KALV
2 of 5 bullish or bearish reports moved the stock their way by T+5. Best: +4.15% at T+5 after the Apr 17, 2026 report. 2 of 5 went positive at some point.
Filters
- Jun 22, 202621w ago 15-12G Bearish 7/10 No price data
- Jun 17, 202621w ago EFFECT Neutral 3/10 Entry $27.00 No price data
- Jun 11, 202622w ago 8-K Neutral 5/10 Entry $26.99 No price data
- Jun 11, 202622w ago Institutional Cluster Neutral 2/10 Entry $27.00 No price data
- May 19, 202625w ago Insider Cluster Bearish 5/10 Viewing Entry $26.81 to $26.79 ▲ +0.07% +1.31% vs SPY
- May 19, 202625w ago Insider Cluster Neutral 2/10 Entry $26.81 to $26.79 ▼ −0.07% −1.31% vs SPY
- Apr 29, 202628w ago 8-K Bullish 8/10 Entry $26.67 to $26.71 ▲ +0.15% −2.96% vs SPY
- Apr 17, 202630w ago Insider Cluster Bearish 6/10 Entry $20.48 to $19.63 ▲ +4.15% +4.71% vs SPY
- Feb 23, 202638w ago Insider Cluster Bearish 6/10 Entry $15.56 to $16.06 ▼ −3.21% −2.59% vs SPY
- Feb 23, 202638w ago Insider Cluster Bearish 7/10 Entry $15.56 to $16.06 ▼ −3.21% −2.59% vs SPY
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers